Literature DB >> 7431225

Disposition kinetics of ethambutol in man.

C S Lee, D C Brater, J G Gambertoglio, L Z Benet.   

Abstract

Six normal adult volunteers were administered 15 mg/kg of ethambutol (EMB) by a constant-rate 1-hr infusion. Plasma and urine samples were collected up to 24 and 72 hr, respectively. Peak plasma levels following the 1-hr infusion ranged from 11.6 to 15.4 microgram/ml. Subsequent postinfusion EMB levels exhibited multiphasic decay. In the 12-hr period following infusion, EMB levels showed biexponential decay. However, 24-hr plasma levels in all subjects were observed to be higher than those predicted using a two-compartment body model. The alpha phase in these subjects had a mean half-life of 8.6 min while the half-life of the beta phase ranged from 2.5 to 3.6 hr (mean 3.1). The half-life of the gamma phase estimated from plasma data points between 12 and 24 hr averaged 1.2 +/- 3.6 hr. A terminal gamma t1/2 of 15.4 +/- 1.7 hr was calculated from 12-72 hr urine data. The mean value for the steady-state volume of distribution using a noncompartmental method was 3.89 liters/kg. Plasma EMB clearance ranged from 7.47 to 8.87 ml/min/kg (mean 8.57). The fraction of the dose eliminated unchanged varied from 0.75 to 0.84 (mean 0.79). Renal clearance ranged from 5.93 to 8.45 ml/min/kg (mean 6.81), indicating active tubular secretion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7431225     DOI: 10.1007/bf01059382

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  13 in total

1.  THE ABSORPTION, EXCRETION, AND METABOLIC FATE OF ETHAMBUTOL IN MAN.

Authors:  E A PEETS; W M SWEENEY; V A PLACE; D A BUYSKE
Journal:  Am Rev Respir Dis       Date:  1965-01

2.  Pharmacokinetic modeling of the dogfish shark (Squalus acanthias): distribution and urinary and biliary excretion of phenol red and its glucuronide.

Authors:  P M Bungay; R L Dedrick; A M Guarino
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

3.  Kinetics of ethambutol elimination in renal disease.

Authors:  T G Christopher; A Blair; A Forrey; R E Cutler
Journal:  Proc Clin Dial Transplant Forum       Date:  1973

4.  [Blood and humoral determination of ethambutol administered by intravenous perfusion].

Authors:  J C Pujet; C Pujet
Journal:  Bord Med       Date:  1972-05

5.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

6.  Metabolic and special studies of ethambutol in normal volunteers and tuberculous patients.

Authors:  V A Place; E A Peets; D A Buyske; R R Little
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

7.  Gas-liquid chromatographic determination of ethambutol in plasma and urine of man and monkey.

Authors:  C S Lee; L Z Benet
Journal:  J Chromatogr       Date:  1976-11-17

8.  [Pharmacokinetics of ethambutol in healthy individuals and in patients with terminal renal failure].

Authors:  T Dume; C Wagner; E Wetzels
Journal:  Dtsch Med Wochenschr       Date:  1971-09-03       Impact factor: 0.628

9.  Kinetics of oral ethambutol in the normal subject.

Authors:  C S Lee; J G Gambertoglio; D C Brater; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

10.  Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol.

Authors:  C S Lee; T C Marbury; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02
View more
  20 in total

1.  The management of tuberculous meningitis.

Authors:  M Humphries
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

2.  Determination of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs.

Authors:  N Watari; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

3.  Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects.

Authors:  R A Blouin; J Kneer; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

4.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

5.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

6.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

Review 7.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

8.  Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.

Authors:  Lindsey H M Te Brake; Jeroen J M W van den Heuvel; Aaron O Buaben; Reinout van Crevel; Albert Bilos; Frans G Russel; Rob E Aarnoutse; Jan B Koenderink
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

9.  Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 10.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.